Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engages in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. The company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

MLYS Profile, Market Tickers and Other

MLYS profile